series-a
Stage
1
Investors
About
Biohabit develops a non-invasive point-of-care diagnostic test that uses oral fluid to measure NT-proBNP, enabling faster and easier diagnosis of heart failure.
Explore Biohabit's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.